ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 435

CIP2A Facilitates Apoptotic Resistance of Fibroblast-Like Synoviocytes in Rheumatoid Arthritis Independent of c-Myc Expression

Jaejoon Lee1, Jiwon Hwang1, Jinseok Kim2, Joong Kyong Ahn3, Hoon-Suk Cha1 and Eun-Mi Koh4, 1Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, South Korea, 2Internal Medicine, Jeju National University Hospital, Jeju, South Korea, 3Department of Medicine, Kangbuk Samsung hospital, Sungkyunkwan University School of Medicine, Seoul, South Korea, 4Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Seoul, South Korea

Meeting: 2012 ACR/ARHP Annual Meeting

Keywords: Apoptosis, fibroblasts and rheumatoid arthritis (RA)

  • Tweet
  • Email
  • Print
Session Information

Title: Rheumatoid Arthritis - Human Etiology and Pathogenisis

Session Type: Abstract Submissions (ACR)

Background/Purpose:

Cancerous inhibitor of protein phosphatase 2A (CIP2A) is a recently identified oncoprotein that leads to cellular proliferation in cancer cells by stabilizing c-Myc protein. The effect of CIP2A in stabilizing c-Myc by inhibition of protein phosphatase 2A activity is a prerequisite step in tumor cell growth and in vivo tumor formation. We have previously shown that CIP2A is expressed in rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS), and that its expression is strongly associated with histopathological synovitis score and invasive function of RA FLS. The aim of this study is to investigate the effects of CIP2A on the apoptosis of RA FLS and to determine the signaling pathway through which dysfunctional apoptosis is facilitated.

Methods:

Proliferation and apoptotic activity of RA FLS following treatment with CIP2A siRNA or control siRNA were analyzed using MTT assays and Cell Death Detection ELISA kit. RA FLS was treated with CIP2A siRNA or control siRNA in 3, 6, and 9 day intervals for a Western blot analysis to determine C-Myc expression. To evaluate the signal transduction pathways engaged in apoptosis, caspase-3 activity, caspase-9 activity, PARP, and phosphorylation of the Akt kinase were analyzed by Western blot analysis.

Results:

Cell viability of RA FLS, as measured by MTT assay, was significantly lower in the CIP2A siRNA-treated group compared with the control after 7 days (p=0.022). Apoptosis of RA FLS, as measured by DNA fragmentation, was significantly higher in the CIP2A siRNA-treated group compared with the control when incubated for 3, 6 and 9 days (p= 0.029, p=0.021, p=0.043, respectively). Interestingly, c-Myc expression, as determined by Western blot analysis, did not change with the different incubation periods. CIP2A siRNA-treated FLS expressed higher level of activated caspase-3, caspase-9, and PARP (p=0.014, p=0.020, p=0.021, respectively) and lower level of phosphorylated Akt (p=0.001) compared with those treated with the control siRNA.

Conclusion:

Our data show that CIP2A expression in RA FLS is an important mediator of dysfunctional apoptosis independent of c-Myc stabilization. Expression of CIP2A may contribute to apoptotic resistance of RA FLS through activation of Akt and deactivation of caspase-3, caspase-9, and PARP. Inhibition of CIP2A may therefore constitute a novel, promising therapeutic target in RA.


Disclosure:

J. Lee,
None;

J. Hwang,
None;

J. Kim,
None;

J. K. Ahn,
None;

H. S. Cha,
None;

E. M. Koh,
None.

  • Tweet
  • Email
  • Print

« Back to 2012 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/cip2a-facilitates-apoptotic-resistance-of-fibroblast-like-synoviocytes-in-rheumatoid-arthritis-independent-of-c-myc-expression/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology